GT201400217A - "anticuerpos anti-baff-anti-il-17 biespecificos" - Google Patents
"anticuerpos anti-baff-anti-il-17 biespecificos"Info
- Publication number
- GT201400217A GT201400217A GT201400217A GT201400217A GT201400217A GT 201400217 A GT201400217 A GT 201400217A GT 201400217 A GT201400217 A GT 201400217A GT 201400217 A GT201400217 A GT 201400217A GT 201400217 A GT201400217 A GT 201400217A
- Authority
- GT
- Guatemala
- Prior art keywords
- baff
- antibodies
- arthritis
- lupus
- psoriassic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
LOS ANTICUERPOS BIESPECÍFICOS SE PROPORCIONAN QUE SE UNEN ESPECÍFICAMENTE DE CÉLULAS B FACTOR DE ACTIVACIÓN DE LA FAMILIA DE TNF (BAFF) Y LA INTERLEUCINA-17A (IL-17) Y SE CARACTERIZAN POR TENER ALTA AFINIDAD Y FUERTES PROPIEDADES NEUTRALIZANTES TANTO BAFF E IL-17.SE ESPERA QUE LOS ANTICUERPOS BIESPECÍFICOS DE LA INVENCIÓN SEAN ÚTILES EN EL TRATAMIENTO DE LA NEFRITIS LÚPICA (LN), EL LUPUS ERITEMATOSO SISTÉMICO (LES), ARTRITIS REUMATOIDE (AR), PSORIASIS (PS), LA ESPONDILITIS ANQUILOSANTE (AS), LA ARTRITIS PSORIÁSICA (AP), PRIMARIA SÍNDROME DE SJÖGREN (PSS), O MIELOMA MÚLTIPLE (MM).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636302P | 2012-04-20 | 2012-04-20 | |
| US201361768747P | 2013-02-25 | 2013-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201400217A true GT201400217A (es) | 2015-06-02 |
Family
ID=48539373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201400217A GT201400217A (es) | 2012-04-20 | 2014-10-15 | "anticuerpos anti-baff-anti-il-17 biespecificos" |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US9359448B2 (es) |
| EP (2) | EP2838920B1 (es) |
| JP (1) | JP6216772B2 (es) |
| KR (1) | KR101673735B1 (es) |
| CN (1) | CN104220455B (es) |
| AP (1) | AP2014008002A0 (es) |
| AR (1) | AR090626A1 (es) |
| AU (1) | AU2013249546B2 (es) |
| BR (1) | BR112014025649A2 (es) |
| CA (1) | CA2869148C (es) |
| CL (1) | CL2014002616A1 (es) |
| CO (1) | CO7160039A2 (es) |
| CR (1) | CR20140466A (es) |
| CY (1) | CY1118824T1 (es) |
| DK (1) | DK2838920T3 (es) |
| DO (1) | DOP2014000234A (es) |
| EA (1) | EA029185B1 (es) |
| EC (1) | ECSP14023405A (es) |
| ES (2) | ES2789474T3 (es) |
| GT (1) | GT201400217A (es) |
| HK (1) | HK1201862A1 (es) |
| HR (1) | HRP20170468T1 (es) |
| HU (1) | HUE032153T2 (es) |
| IL (1) | IL234965B (es) |
| IN (1) | IN2014MN01876A (es) |
| LT (1) | LT2838920T (es) |
| ME (1) | ME02596B (es) |
| MX (1) | MX367460B (es) |
| MY (1) | MY173282A (es) |
| NZ (1) | NZ630865A (es) |
| PE (1) | PE20142147A1 (es) |
| PH (1) | PH12014502333A1 (es) |
| PL (1) | PL2838920T3 (es) |
| PT (1) | PT2838920T (es) |
| RS (1) | RS55729B1 (es) |
| SG (1) | SG11201406726PA (es) |
| SI (1) | SI2838920T1 (es) |
| TW (1) | TWI585103B (es) |
| WO (1) | WO2013158577A1 (es) |
| ZA (1) | ZA201407272B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2012149227A (ru) | 2010-05-20 | 2014-06-27 | Аблинкс Нв | Биологические материалы, относящиеся к her3 |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| AR090626A1 (es) * | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
| TW201444867A (zh) | 2013-03-08 | 2014-12-01 | Lilly Co Eli | 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體 |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
| EP3409110A1 (en) | 2013-11-19 | 2018-12-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| EA033604B1 (ru) | 2014-01-31 | 2019-11-08 | Boehringer Ingelheim Int | Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид |
| AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
| US10280231B2 (en) * | 2015-07-23 | 2019-05-07 | Boehringer Ingelheim International Gmbh | Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof |
| CN105061596B (zh) * | 2015-08-05 | 2019-01-29 | 江苏诺迈博生物医药科技有限公司 | 人b淋巴细胞刺激因子的单克隆抗体及其应用 |
| EP3735272A4 (en) * | 2018-01-05 | 2021-09-22 | Biograph 55, Inc. | COMPOSITIONS AND METHODS FOR IMMUNO CANCEROTHERAPY |
| CN117529506A (zh) * | 2021-06-11 | 2024-02-06 | 海南先声药业有限公司 | 抗人il-17抗体和taci的双功能融合蛋白分子 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| AR035119A1 (es) * | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
| EP1928506A4 (en) * | 2005-08-19 | 2009-10-21 | Abbott Lab | IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF |
| PT1963368E (pt) * | 2005-12-13 | 2012-09-14 | Lilly Co Eli | Anticorpos anti-il-17 |
| US20110293629A1 (en) * | 2010-05-14 | 2011-12-01 | Bastid Jeremy | Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists |
| AR090626A1 (es) * | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
-
2013
- 2013-04-08 AR ARP130101134A patent/AR090626A1/es active IP Right Grant
- 2013-04-12 TW TW102113167A patent/TWI585103B/zh not_active IP Right Cessation
- 2013-04-16 ES ES17153380T patent/ES2789474T3/es active Active
- 2013-04-16 CN CN201380020761.7A patent/CN104220455B/zh active Active
- 2013-04-16 LT LTEP13726321.6T patent/LT2838920T/lt unknown
- 2013-04-16 EA EA201491622A patent/EA029185B1/ru not_active IP Right Cessation
- 2013-04-16 ME MEP-2017-41A patent/ME02596B/me unknown
- 2013-04-16 IN IN1876MUN2014 patent/IN2014MN01876A/en unknown
- 2013-04-16 NZ NZ630865A patent/NZ630865A/en not_active IP Right Cessation
- 2013-04-16 BR BR112014025649A patent/BR112014025649A2/pt not_active Application Discontinuation
- 2013-04-16 EP EP13726321.6A patent/EP2838920B1/en active Active
- 2013-04-16 RS RS20170160A patent/RS55729B1/sr unknown
- 2013-04-16 MX MX2014012692A patent/MX367460B/es active IP Right Grant
- 2013-04-16 WO PCT/US2013/036677 patent/WO2013158577A1/en active Application Filing
- 2013-04-16 ES ES13726321.6T patent/ES2621917T3/es active Active
- 2013-04-16 SI SI201330522A patent/SI2838920T1/sl unknown
- 2013-04-16 HU HUE13726321A patent/HUE032153T2/en unknown
- 2013-04-16 EP EP17153380.5A patent/EP3192809B1/en active Active
- 2013-04-16 KR KR1020147028867A patent/KR101673735B1/ko active IP Right Grant
- 2013-04-16 PL PL13726321T patent/PL2838920T3/pl unknown
- 2013-04-16 PT PT137263216T patent/PT2838920T/pt unknown
- 2013-04-16 SG SG11201406726PA patent/SG11201406726PA/en unknown
- 2013-04-16 PE PE2014001619A patent/PE20142147A1/es active IP Right Grant
- 2013-04-16 MY MYPI2014703075A patent/MY173282A/en unknown
- 2013-04-16 CA CA2869148A patent/CA2869148C/en active Active
- 2013-04-16 JP JP2015507095A patent/JP6216772B2/ja active Active
- 2013-04-16 AP AP2014008002A patent/AP2014008002A0/xx unknown
- 2013-04-16 AU AU2013249546A patent/AU2013249546B2/en not_active Ceased
- 2013-04-16 DK DK13726321.6T patent/DK2838920T3/en active
- 2013-04-16 US US13/863,544 patent/US9359448B2/en active Active
-
2014
- 2014-09-30 CL CL2014002616A patent/CL2014002616A1/es unknown
- 2014-10-02 IL IL234965A patent/IL234965B/en active IP Right Grant
- 2014-10-06 CR CR20140466A patent/CR20140466A/es unknown
- 2014-10-07 ZA ZA2014/07272A patent/ZA201407272B/en unknown
- 2014-10-15 GT GT201400217A patent/GT201400217A/es unknown
- 2014-10-16 DO DO2014000234A patent/DOP2014000234A/es unknown
- 2014-10-17 PH PH12014502333A patent/PH12014502333A1/en unknown
- 2014-10-17 EC ECIEPI201423405A patent/ECSP14023405A/es unknown
- 2014-10-20 CO CO14231938A patent/CO7160039A2/es unknown
-
2015
- 2015-03-12 HK HK15102524.4A patent/HK1201862A1/xx not_active IP Right Cessation
-
2016
- 2016-05-18 US US15/157,782 patent/US9708402B2/en active Active
-
2017
- 2017-03-21 HR HRP20170468TT patent/HRP20170468T1/hr unknown
- 2017-03-27 CY CY20171100380T patent/CY1118824T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201400217A (es) | "anticuerpos anti-baff-anti-il-17 biespecificos" | |
| EP4257613A3 (en) | Bispecific checkpoint inhibitor antibodies | |
| CL2013001213A1 (es) | Anticuerpo para interleuquina 17 (il-17); uso de este para tratar artritis reumatoide. | |
| CL2016001079A1 (es) | Nuevos compuestos para el combate de artrópodos. | |
| CL2017001382A1 (es) | Anticuerpos anti-cd38 para el tratamiento de leucemia mieloide aguda | |
| PE20150002A1 (es) | Anticuerpos anti-fcrn | |
| BR112016008541A2 (pt) | composições úteis para tratar distúrbios relacionados a kit | |
| EA201490454A1 (ru) | Тернесит в качестве активатора для латентно-гидравлических и пуццолановых веществ | |
| EA201391175A1 (ru) | Гетеродимерные иммуноглобулины | |
| BR112013023306A2 (pt) | métodos para tratar pelo menos uma parte de uma formação subterrânea | |
| EA201590270A1 (ru) | Применение биотина для лечения рассеянного склероза | |
| MX2016006101A (es) | Agente ligante de la il-17a y usos del mismo. | |
| BR112014001834A2 (pt) | biocontrole de nematoides | |
| BR112014000397A2 (pt) | processo para a preparação de pelo menos uma nitrila | |
| FR3015498B1 (fr) | Composition elastomerique ayant une disperson de charge amelioree | |
| FR2960913B1 (fr) | Prechauffage d'une bougie d'allumage | |
| EA201391563A1 (ru) | Твердое вещество полихлоропрен с тиксотропными свойствами | |
| DK3604184T3 (da) | Anvendelse af miljøvenligt granulat | |
| BRPI1011503A2 (pt) | processo para separar os componentes de uma mistura. | |
| TN2014000413A1 (en) | Anti-baff-anti-il-17 bispecific antibodies | |
| TH1401006266A (th) | แอนติ-baff-แอนติ-il-17ไบสเปซิฟิกแอนติบอดี | |
| Puttemans et al. | Tobcat project results: applying object categorisation techniques in real-life industrial cases | |
| TH1601002596A (th) | การจัดสูตรยาฉีดน้ำมันงาเป็นหลัก | |
| FR3006600B1 (fr) | Procede de valorisation de boues grasses, notamment de boues grasses de laminoir | |
| CN302520709S (zh) | 组合前照灯（s15） |